证券代码：600211 证券简称：西藏药业 公告编号：2025-033 西藏诺迪康药业股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本公司于 2025 年 8 月 27 日召开第八届董事会第三次临时会议，审议通过了《关于对 外投资涉及关联交易的议案》，公司将于 2025 年 9 月 15 日召开 2025 年第二次临时股东 大会，并发布了关于召开 2025 年第二次临时股东大会的相关通知（详见公司于 2025 年 8 月 28 日发布在《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 www.sse.com.cn 的相关公告）。为确保公司股东充分了解本次股东大会的相关信息，现 将有关事项提示公告如下： 一、 召开会议的基本情况 (一)股东大会类型和届次 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 股东大会召开日期：2025年9月15日 本次股东大会采用的网络投票系 ...

西藏诺迪康药业股份有限公司 2025 年第二次临时股东大会文件 1 关于对外投资涉及关联交易的议案 各位股东： 企业名称：Accuredit Therapeutics Limited（成立于开曼群岛） 类型：Exempted company（豁免公司） 成立时间：2021 年 8 月 4 日 注册编号：379645 董事长：王永忠 授权资本：5 万美元 注册地：Palm Grove Unit 4, 265 Smith Road, George Town, P.O. Box 52A Edgewater Way, #1653, Grand Cayman KY1-9006, Cayman Islands 标的公司Accuredit Therapeutics Limited专注于开发基于LNP和其他非病毒载体的体内 基因编辑技术和产品，致力于为全球患者提供终生只需一次用药且具备成本优势的创新治 疗方案。该公司核心资产和主要业务集中于其在国内通过 VIE 架构控制的锐正基因（苏州） 有限公司（以下简称"锐正基因（苏州）"），从事基因编辑技术等研究。锐正基因（苏州） 目前拥有员工 46 人，王永忠担任 CEO。 为了公司 ...

Core Viewpoint - The biopharmaceutical sector experienced a significant increase of 3.06% on September 5, with Sanofi leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% [1] - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Group 2: Individual Stock Performance - Sanofi (688336) closed at 61.60, with a rise of 11.80% and a trading volume of 165,400 shares, totaling a transaction value of 9.62 billion [1] - Changchun High-tech (000661) closed at 128.00, increasing by 7.53% with a trading volume of 270,100 shares [1] - Junshi Biosciences (688180) closed at 48.00, up 7.38% with a trading volume of 252,900 shares, totaling 1.17 billion [1] - Tibet Pharmaceutical (600211) closed at 50.48, rising by 7.13% with a trading volume of 220,200 shares, totaling 1.08 billion [1] - Other notable stocks include: - Rongan Bio (688331) at 92.17, up 4.32% [1] - Kexing Pharmaceutical (688136) at 42.27, up 4.14% [1] Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 231 million from institutional investors, while retail investors experienced a net outflow of 25.77 million [1]

Core Viewpoint - Xizang Pharmaceutical has a strong profitability driven primarily by its flagship product, "Xinhuosuo," but faces challenges in diversifying its product portfolio and addressing market expectations for future growth [1][3][4]. Financial Performance - The company has recorded profits exceeding 1 billion, ranking fifth in the biopharmaceutical sector, with a total market capitalization of 15 billion and a valuation of 15 times earnings, placing it at the lower end of profitable companies [1]. - Recent financial records show profits of 2.09 billion, 3.70 billion, 8.01 billion, and 10.51 billion over the last four years, indicating a consistent upward trend [1]. - Xinhuosuo accounted for approximately 88% of the company's revenue in the first half of 2025, generating 14.56 billion out of a total of 16.51 billion [1][6]. Product Overview - The product lineup is heavily reliant on Xinhuosuo, with other products contributing only 11.64% to total revenue [3][7]. - Xinhuosuo, launched in 2005, is the first gene-engineered drug for acute heart failure treatment in China, with plans to expand production capacity to 15 million units annually starting in 2025 [4][6]. - The drug's clinical advantages include rapid onset of action within 30 minutes, compared to traditional medications that take 1-2 hours, and it protects kidney function while promoting sodium excretion [4][6]. Strategic Challenges - The company has faced two significant strategic failures: the acquisition of the drug "Yimuduo" and a failed investment in a COVID-19 mRNA vaccine [9][12]. - The acquisition of Yimuduo for 1.9 billion USD has resulted in substantial impairment losses totaling approximately 766 million RMB due to underperformance and market challenges [11]. - The investment in the Russian mRNA vaccine project has also led to financial losses and strategic setbacks, with the project ultimately being terminated [13][12]. Shareholder Dynamics - The company's ownership structure is complex, with the largest shareholder, Lin Gang, controlling 38.11% of the shares, while the founder, Chen Dabin, retains a significant but minority stake [20][23]. - There is ongoing tension between the controlling shareholder and the founding group, leading to strategic disagreements and governance challenges [24]. Future Outlook - The market exclusivity for Xinhuosuo is expected to last until 2033, but future revenue will depend on the successful expansion into new indications and the transition to water-based injections [7][6]. - The company is exploring collaborations with SGLT2 inhibitors to enhance treatment outcomes for chronic heart failure [6].

华夏行业景气混合（003567）基金经理为钟帅。 资料显示，西藏诺迪康药业股份有限公司位于西藏自治区拉萨经济技术开发区A区广州路3号,四川省成 都市锦江区三色路427号，成立日期1999年7月14日，上市日期1999年7月21日，公司主营业务涉及医药 制造。主营业务收入构成为：药品销售99.80%，其他(补充)0.20%。 从西藏药业十大流通股东角度 数据显示，华夏基金旗下1只基金位居西藏药业十大流通股东。华夏行业景气混合（003567）二季度持 有股数190.36万股，持股数量与上期相比不变，占流通股的比例为0.59%。根据测算，今日浮亏损失约 487.33万元。 华夏行业景气混合（003567）成立日期2017年2月4日，最新规模72.61亿。今年以来收益40.02%，同类 排名1173/8180；近一年收益84.25%，同类排名619/7978；成立以来收益329.74%。 9月4日，西藏药业跌5.14%，截至发稿，报47.23元/股，成交5.88亿元，换手率3.75%，总市值152.23亿 元。 截至发稿，钟帅累计任职时间5年40天，现任基金资产总规模82.53亿元，任职期间最佳基金回报 151.22 ...

Company Overview - Tibet Pharmaceutical Co., Ltd. is located in Lhasa Economic and Technological Development Zone and was established on July 14, 1999, with its listing date on July 21, 1999 [1] - The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales and 0.20% from other sources [1] Stock Performance - As of September 4, the stock price of Tibet Pharmaceutical decreased by 2.01%, trading at 48.79 CNY per share, with a total market capitalization of 15.726 billion CNY [1] - Year-to-date, the stock has increased by 39.13%, with a 1.75% rise over the last five trading days, 19.94% over the last 20 days, and 31.44% over the last 60 days [1] Financial Performance - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion CNY, representing a year-on-year growth of 2.23%, while the net profit attributable to shareholders decreased by 8.96% to 567 million CNY [2] - The company has distributed a total of 2.258 billion CNY in dividends since its A-share listing, with 1.580 billion CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 8.08% to 45,200, while the average number of circulating shares per person increased by 8.79% to 7,132 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 2.5902 million shares, a decrease of 1.6084 million shares from the previous period [3]

Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

Meeting Details - The annual general meeting was held on September 2, 2025, at the company's office in Chengdu, Sichuan Province [1] - The meeting was presided over by Chairman Chen Dabing, and the voting method complied with the Company Law and Articles of Association [1] Attendance and Voting Results - The meeting had participation from ordinary shareholders and preferred shareholders with restored voting rights [1] - The voting results for the non-cumulative voting proposals showed a high approval rate, with the following details: - Proposal 1: 99.6975% approval from A-shareholders [1] - Proposal 2: 99.8543% approval from A-shareholders [1] - Proposal 3: 99.8271% approval from A-shareholders [1] - Proposal 4: 99.8574% approval from A-shareholders [1] Legal Compliance - The meeting's convening, procedures, and voting were confirmed to be in compliance with the Company Law, Shareholders' Meeting Rules, and other relevant regulations [2]

泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2025年第一次临时股东大会的 法律意见 6 2025年9月2日 中国·成都市天府新区隆和西巷 299 号 泰和泰中心 21—33F 21-33f, Tahota Center, No.299 Longhe West Lane, Tianfu New District, Chengdu, People's Republic of China 电话 | TEL: 86-28-8662 5656 本次股东大会由公司董事长陈达彬主持，于 2025年９月２日 14 点 30 分在四川省成都市锦江区三色路 427 号公司办公楼会议室召开。 www.tahota.com 泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致： 西藏诺迪康药业股份有限公司 故启者 泰和泰律师事务所（以下简称"泰和泰"或"本所"）作为西藏 诺迪康药业股份有限公司（以下简称"西藏药业"或"公司"）的常 年法律顾问, 现接受公司的委托, 指派谭蕾、刘化勇律师出席公司 2025 年第一次临时股东大会，并依据《中华人民共和国公司法》（以下简 称"《公司法》" ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-032 西藏诺迪康药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 2 日 | 1、出席会议的股东和代理人人数 | 690 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 180,984,839 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 56.1508 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 本次股东大会由董事长陈达彬先生主持，大会的表决方式符合《公司法》及《公司章 程》的规定。 (五)公司董事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：关于取消监事会的议案 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 ...